Citation sources

Updated weekly. Details via Crossref
Crossref Scopus Google Scholar
44 43 Search
2024
Inhibition of pannexin‐1 does not restore electrolyte balance in precystic Pkd1 knockout mice
Physiological Reports
2024
Montelukast improves disease outcome in SOD1G93A female mice by counteracting oligodendrocyte dysfunction and aberrant glial reactivity
British Journal of Pharmacology
2024
Inflammasomes in neurological disorders — mechanisms and therapeutic potential
Nature Reviews Neurology
2024
Exercise training induces mild skeletal muscle adaptations without altering disease progression in a TDP-43 mouse model
Journal of Applied Physiology
2024
A current review on P2X7 receptor antagonist patents in the treatment of neuroinflammatory disorders: a patent review on antagonists
Naunyn-Schmiedeberg's Archives of Pharmacology
2024
Sex biology in amyotrophic lateral sclerosis
Ageing Research Reviews
2024
Role and therapeutic targets of P2X7 receptors in neurodegenerative diseases
Frontiers in Immunology
2024
Unlocking the therapeutic potential of P2X7 receptor: a comprehensive review of its role in neurodegenerative disorders
Frontiers in Pharmacology
2023
Handbook of Animal Models in Neurological Disorders
2023
Role of the P2 × 7 receptor in neurodegenerative diseases and its pharmacological properties
Cell & Bioscience
2023
Inflammasome Biology
2023
Purinergic Signaling in Neurodevelopment, Neuroinflammation and Neurodegeneration
2023
Animal Models for the Investigation of P2X7 Receptors
International Journal of Molecular Sciences
2022
The Role of Epigenetics in Neuroinflammatory-Driven Diseases
International Journal of Molecular Sciences
2022
miR-23a suppression accelerates functional decline in the rNLS8 mouse model of TDP-43 proteinopathy
Neurobiology of Disease
2022
P2X7 receptor activation mediates superoxide dismutase 1 (SOD1) release from murine NSC-34 motor neurons
Purinergic Signalling
2022
Rethinking purinergic concepts and updating the emerging role of P2X7 and P2X4 in amyotrophic lateral sclerosis
Neuropharmacology
2022
Purinergic P2X7 Receptor: A Therapeutic Target in Amyotrophic Lateral Sclerosis
ACS Chemical Neuroscience
2021
P2X7 receptor antagonism increases regulatory T cells and reduces clinical and histological graft-versus-host disease in a humanised mouse model
Clinical Science
2021
Inflammasome activation in neurodegenerative diseases
Essays in Biochemistry
2021
P2X7 Receptors in Neurodegeneration: Potential Therapeutic Applications From Basic to Clinical Approaches
Frontiers in Cellular Neuroscience
2021
ATP and adenosine—Two players in the control of seizures and epilepsy development
Progress in Neurobiology
2021
Novel P2X7 Antagonist Ameliorates the Early Phase of ALS Disease and Decreases Inflammation and Autophagy in SOD1-G93A Mouse Model
International Journal of Molecular Sciences
2021
Microglia RAGE exacerbates the progression of neurodegeneration within the SOD1G93A murine model of amyotrophic lateral sclerosis in a sex-dependent manner
Journal of Neuroinflammation
2021
Inflammasome in ALS Skeletal Muscle: NLRP3 as a Potential Biomarker
International Journal of Molecular Sciences
2020
The P2X7 Receptor: Central Hub of Brain Diseases
Frontiers in Molecular Neuroscience
2020
P2X7 Receptors Amplify CNS Damage in Neurodegenerative Diseases
International Journal of Molecular Sciences
2020
Chronic administration of P2X7 receptor antagonist JNJ-47965567 delays disease onset and progression, and improves motor performance in ALS SOD1G93A female mice
Disease Models & Mechanisms
2020
P2X7 activation enhances skeletal muscle metabolism and regeneration in SOD1G93A mouse model of amyotrophic lateral sclerosis
Brain Pathology
2020
The P2X7 receptor antagonist JNJ-47965567 administered thrice weekly from disease onset does not alter progression of amyotrophic lateral sclerosis in SOD1G93A mice
Purinergic Signalling
2020
The purinergic P2X7 receptor as a potential drug target to combat neuroinflammation in neurodegenerative diseases
Medicinal Research Reviews
2020
Duality of P2X7 Receptor in Amyotrophic Lateral Sclerosis
Frontiers in Pharmacology
2020
P2X7 Receptor Antagonism as a Potential Therapy in Amyotrophic Lateral Sclerosis
Frontiers in Molecular Neuroscience
2019
LPS-Induced Systemic Neonatal Inflammation: Blockage of P2X7R by BBG Decreases Mortality on Rat Pups and Oxidative Stress in Hippocampus of Adult Rats
Frontiers in Behavioral Neuroscience
2019
Ligand-independent activation of the P2X7 receptor by Hsp90 inhibition stimulates motor neuron apoptosis
Experimental Biology and Medicine
2019
Increased expression of the P2X7 receptor in temporal lobe epilepsy: Animal models and clinical evidence
Molecular Medicine Reports
2019
Dynamic interplay between H-current and M-current controls motoneuron hyperexcitability in amyotrophic lateral sclerosis
Cell Death & Disease
2019
Long-term treatment with the P2X7 receptor antagonist Brilliant Blue G reduces liver inflammation in a humanized mouse model of graft-versus-host disease
Cellular Immunology
2018
The potential of P2X7 receptors as a therapeutic target, including inflammation and tumour progression
Purinergic Signalling
2018
P2X7 as a scavenger receptor for innate phagocytosis in the brain
British Journal of Pharmacology
2017
Advances in Experimental Medicine and Biology
2017
P2X7 Receptor Activation Modulates Autophagy in SOD1-G93A Mouse Microglia
Frontiers in Cellular Neuroscience
2017
P2X7 receptor antagonism in amyotrophic lateral sclerosis
Neural Regeneration Research
2017
The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease
Clinical and Experimental Immunology